Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer.
Clin Cancer ResSep 1, 2026
Martin Smoragiewicz, Alice Bernard-Tessier, Mark Linch et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase Ib trial assessed the safety and pharmacokinetics of bavdegalutamide combined with abiraterone in 45 patients with metastatic prostate cancer (mPC) experiencing PSA progression. The study found a PSA control rate of 48.9% and a median radiographic progression-free survival (rPFS) of 16.3 months, indicating potential clinical activity of the combination therapy.
Key findings
- PSA control rate was 48.9% (95% CI, 33.7-64.2).
- PSA50 response rate was 24.4% (95% CI, 12.9-39.5).
- Median rPFS was 16.3 months (95% CI, 8.2-not calculable).
- No dose-limiting toxicities were observed.
Why it matters
The findings suggest that combining bavdegalutamide with abiraterone may offer a new therapeutic option for patients with mPC who have progressed on standard treatment, potentially improving patient outcomes.